CymaBay Therapeutics

Primary biliary cholangitis (PBC) is a rare, chronic, autoimmune liver disease that progressively destroys the liver’s bile ducts.   To learn more, visit: https://bit.ly/3KRMfjT #PrimaryBiliaryCholangitis #LiverDisease #Hepatology #PBC

Listening to and learning from the patient advocacy community is critical in understanding where unmet needs really lie and how we can best support the community’s evolving priorities. Last week at #EASLCongress, CymaBay and Gilead Sciences had the honor to hear from patient advocacy leaders in primary biliary cholangitis (PBC) from around the world. Their passion and insights on how to improve holistic PBC care were inspiring. Thank you everyone that joined us for this early morning discussion! #PrimaryBiliaryCholangitis #LiverDisease #Hepatology #PBC #Patientfirst

Learn more about the unmet needs in #PrimaryBiliaryCholangitis today and how Gilead Sciences is working to create a healthier future for people living with PBC and #LiverDisease.   #EASLCongress #LiverDisease #Hepatology #PBC #PrimaryBiliaryCholangitis

#EASLCongress is a highlight of the #hepatology calendar and 2024 was a strong year for advances in PBC science. We were pleased to connect with so many stakeholders from across the PBC community in our collective efforts to improve the treatment and quality of life for people living with PBC. Thank you EASL | The Home of Hepatology for a great meeting!   If you were not able to join us onsite, access our EASL presentations here: https://bit.ly/4ceH9K1   #PrimaryBiliaryCholangitis #LiverDisease #Hepatology #PBC

Today we are excited to be at EASL | The Home of Hepatology 2024 Conference in Milan, Italy, where we will present interim long-term results from the ongoing ASSURE study of our investigational therapy in primary biliary cholangitis. Learn more: https://bit.ly/4eadqnl #EASLCongress #PrimaryBiliaryCholangitis #LiverDisease #Hepatology #Gastroenterology #PBC

A study from the Cleveland Clinic reported that almost half of men in the U.S. don’t attend an annual physician exam. This Men’s Health Month, we encourage men to prioritize their health by making an appointment particularly if they are experiencing unexplained symptoms. Primary biliary cholangitis (PBC) is a rare, chronic, autoimmune liver disease in which people can experience pruritus (intense itch) and fatigue. Unfortunately, a myth that PBC doesn’t impact men can delay diagnosis and treatment. If left untreated, PBC can develop into cirrhosis, liver failure, and liver cancer. Early detection is key. To learn more about discussing PBC with a doctor, please visit: https://bit.ly/4e7bbkH #MensHealthMonth #PrimaryBiliaryCholangitis #PBC #Hepatology #LiverDisease #LiverHealth

We are excited to join the liver community at next week’s #EASLCongress 2024 in Milan, Italy, to meet with hepatology experts and share our latest findings in our work to advance care for people living with #PrimaryBiliaryCholangitis. If you are attending, please stop by and visit our booth to learn more about #PBC. We look forward to seeing you there! #LiverDisease #Hepatology

This week at #DDW2024 our team had the opportunity to connect with experts from across the U.S. passionate about advancing care for people with liver diseases and #PrimaryBiliaryCholangitis. Thank you, Digestive Disease Week® (DDW), for the robust programming and to everyone we met on site, we left inspired and ready to keep pushing forward for better care in PBC.   #PrimaryBiliaryCholangitis #LiverDisease #Hepatology #PBC

Today is #ClinicalTrialsDay and we are pleased to join the clinical research community led by the ACRP - Association of Clinical Research Professionals to celebrate the trailblazers who push forward scientific discovery each day and share our deep gratitude with every person that has taken part in a clinical research study. Only through the participation of people living with primary biliary cholangitis can we advance care for this rare disease. Thank you from everyone at CymaBay! To learn more about our ongoing studies in PBC, please visit: https://bit.ly/3ypaD9u   #CTD2024 #PrimaryBiliaryCholangitis #LiverDisease #hepatology #Gastroentereology #PBC 

Today, we will present interim results from the ongoing ASSURE study during the Presidential Plenary of Digestive Disease Week® (DDW) 2024 Conference in Washington, DC. Data provides further evidence of the efficacy and safety profile of our investigational treatment for people living with primary biliary cholangitis (PBC). Learn more: https://bit.ly/3ymaQKK   #DDW2024 #PrimaryBiliaryCholangitis #LiverDisease #Hepatology #Gastroenterology #PBC